gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · PALIHealthcareBiotechnology

Palisade Bio, Inc. Common Stock (PALI)

$1.25+1.63%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$1.25▼ 37.25% in range
Nov 3, 2025Low $1.12 · High $2.80Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Palisade Bio closed at $1.25 on Nov 4, up 1.63%, 55.4% below its 52-week closing high. Volume of 2.0M shares was 0.52× its 20-day average (below normal).

Split-adjusted performance: -16.1% over one month, -37.5% over six months, -37.5% over one year.

In the quarter ended Jun 30, 2026, revenue was $500K, with a net margin of -2114.8%.

Short interest was 31.7M shares at the Oct 15 settlement, up 2.4% from the prior report (18.3% of float, 16.0 days to cover).

Market cap$217.8M174.3M shares
Revenue · quarter$500.0K—
Diluted EPS$-0.05—
P/E · TTM—P/S 435.7×
Net margin-2,114.8%Gross 100.0%
Dividend yieldNone
52-week range1.12 – 2.80−55.4% from high
Volume2.0M0.52× 20-day avg
Volatility · 60d78.2%Annualised
Short % of float18.3%16.0 days to cover
Net cash$125.2MCash $125.2M
Next earnings—Not scheduled
Split-adjusted performance
1W +5.0%1M −16.1%3M −40.2%6M −37.5%YTD −46.8%1Y −37.5%3Y −84.7%5Y −99.9%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum38
Revenue growth—
Net margin20
Value (low P/E)—
Size46

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short31.7M+2.4% vs prior
Days to cover16.0Settled Oct 15
% of float18.3%
Short vol. 10d37.7%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
PALIPalisade Bio$1.25+1.63%−37.5%—−2114.8%—$217.8M
IKTInhibikase Therapeutics$1.57+5.74%−22.1%———$218.4MCompare
PLXProtalix BioTherapeutics$2.69+3.07%+33.2%+27.1%19.0%11.4$216.7MCompare
DTILPrecision BioSciences$8.12+16.50%+8.0%−100.0%——$224.1MCompare
ARTVArtiva Biotherapeutics$4.22+0.48%−65.9%———$206.3MCompare
PROKProKidney$1.12+4.67%−42.9%−32.1%−18948.0%—$234.1MCompare
CABACabaletta Bio$1.420.00%−61.9%———$240.8MCompare
FATEFate Therapeutics$2.09+2.45%−8.7%+9.2%−1448.6%—$250.4MCompare
IVVDInvivyd$0.6336+8.96%−56.6%+21.2%−310.8%—$186.8MCompare

News about Palisade Bio

All news →
Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026GlobeNewswire Inc. · Sep 28, 2026▲ PositivePalisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA ClearanceGlobeNewswire Inc. · Sep 23, 2026▲ PositivePalisade Bio to Participate in Upcoming Investor ConferencesGlobeNewswire Inc. · Sep 3, 2026▲ Positive

Quick answers

What does Palisade Bio do?
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
What is PALI's market cap?
$217.84M, based on the Nov 4 close of $1.25.
Does Palisade Bio pay a dividend?
No regular cash dividend has been paid in the last year.
How much of PALI is sold short?
31.7M shares, 18.3% of float, as of Oct 15, 2026.
What sector is PALI in?
Healthcare, in the Biotechnology industry.

About Palisade Bio

Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.

HQ: Carlsbad, CA14 employeesListed Apr 28, 2021palisadebio.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology